Search

Your search keyword '"Anscombe E"' showing total 25 results

Search Constraints

Start Over You searched for: Author "Anscombe E" Remove constraint Author: "Anscombe E"
25 results on '"Anscombe E"'

Search Results

1. Targeting protein-protein interactions for cancer therapy

2. CDK2/Cyclin A in complex with compound 73

3. CDK1/CyclinB1/CKS2 in complex with NU6102

4. CDK2/Cyclin A covalent complex with 6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-amine (NU6300)

5. Identification and characterization of an irreversible inhibitor of CDK2

6. Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.

7. 325 Identification and characterization of an irreversible inhibitor of CDK2

8. Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors.

9. MORECare research methods guidance development: recommendations for presenting results to stakeholders from palliative and end of life care research

10. MORECare research methods guidance development: recommendations for health economic evaluations in palliative and end of life care research

11. MORECare research methods guidance development:recommendations for statistical methods in palliative and end of life care research

12. MoreCare research methods guidance development : recommendations for using mixed methods to develop and evaluate complex interventions in palliative and end of life care

13. MORECare research methods guidance development : recommendations for statistical methods in palliative and end of life care research

21. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.

22. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.

23. Identification and Characterization of an Irreversible Inhibitor of CDK2.

24. Implementing an aim-based outcome measure in a psychoanalytic child psychotherapy service: insights, experiences and evidence.

25. 8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode.

Catalog

Books, media, physical & digital resources